- Home
- MYNZ vs TRAW Comparison
MYNZ vs TRAW Comparison
Compare MYNZ & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- TRAW
- Stock Information
- Founded
- MYNZ 2021
- TRAW 1998
- Country
- MYNZ Germany
- TRAW United States
- Employees
- MYNZ N/A
- TRAW N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- TRAW
- Sector
- MYNZ Health Care
- TRAW
- Exchange
- MYNZ Nasdaq
- TRAW NYSE
- Market Cap
- MYNZ 8.0M
- TRAW 7.8M
- IPO Year
- MYNZ 2021
- TRAW 2013
- Fundamental
- Price
- MYNZ $2.08
- TRAW $1.65
- Analyst Decision
- MYNZ Buy
- TRAW
- Analyst Count
- MYNZ 2
- TRAW 0
- Target Price
- MYNZ $14.00
- TRAW N/A
- AVG Volume (30 Days)
- MYNZ 93.5K
- TRAW 3.5M
- Earning Date
- MYNZ 06-17-2025
- TRAW 05-15-2025
- Dividend Yield
- MYNZ N/A
- TRAW N/A
- EPS Growth
- MYNZ N/A
- TRAW N/A
- EPS
- MYNZ N/A
- TRAW N/A
- Revenue
- MYNZ $893,991.00
- TRAW $227,000.00
- Revenue This Year
- MYNZ $26.06
- TRAW $3.81
- Revenue Next Year
- MYNZ $4.97
- TRAW $30.43
- P/E Ratio
- MYNZ N/A
- TRAW N/A
- Revenue Growth
- MYNZ N/A
- TRAW 0.44
- 52 Week Low
- MYNZ $1.92
- TRAW $0.97
- 52 Week High
- MYNZ $34.00
- TRAW $19.44
- Technical
- Relative Strength Index (RSI)
- MYNZ 38.07
- TRAW 54.15
- Support Level
- MYNZ $1.93
- TRAW $1.30
- Resistance Level
- MYNZ $2.10
- TRAW $2.58
- Average True Range (ATR)
- MYNZ 0.16
- TRAW 0.23
- MACD
- MYNZ 0.04
- TRAW 0.07
- Stochastic Oscillator
- MYNZ 30.39
- TRAW 34.04
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.